太龙药业
(600222)
| 流通市值：42.62亿 | | | 总市值：42.62亿 |
| 流通股本：5.59亿 | | | 总股本：5.59亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 738,044,648.29 | 350,227,659.49 | 1,757,789,761.61 | 1,186,902,173.45 |
| 营业总成本 | 731,562,312.73 | 347,500,662.61 | 1,661,897,397.98 | 1,166,973,867.61 |
| 其他经营收益 | | | | |
| 营业利润 | 16,440,843.67 | 2,496,637.43 | 77,708,673.5 | 34,536,720.46 |
| 利润总额 | 16,438,145.92 | 2,497,276.47 | 77,505,607.4 | 34,300,494.33 |
| 净利润 | 13,160,737.81 | 2,315,206.46 | 65,867,565.55 | 30,474,636.07 |
| 每股收益 | | | | |
| 其他综合收益 | -3,316,125 | -708,426.44 | -13,818,275.06 | -20,228,871.94 |
| 综合收益总额 | 9,844,612.81 | 1,606,780.02 | 52,049,290.49 | 10,245,764.13 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,155,037,584.55 | 2,187,040,104.71 | 2,141,204,162.55 | 2,198,942,152.62 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,477,025,176.46 | 1,488,181,781.8 | 1,500,324,164.43 | 1,539,359,820.57 |
| 资产总计 | 3,632,062,761.01 | 3,675,221,886.51 | 3,641,528,326.98 | 3,738,301,973.19 |
| 流动负债: | | | | |
| 流动负债合计 | 1,708,278,171.95 | 1,736,834,813.75 | 1,873,622,268.93 | 1,903,287,432.06 |
| 非流动负债: | | | | |
| 非流动负债合计 | 253,253,898.61 | 274,232,215.1 | 105,357,980.41 | 185,524,185.32 |
| 负债合计 | 1,961,532,070.56 | 2,011,067,028.85 | 1,978,980,249.34 | 2,088,811,617.38 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,613,075,386.41 | 1,606,251,567.67 | 1,604,358,827.83 | 1,592,827,901.41 |
| 股东权益合计 | 1,670,530,690.45 | 1,664,154,857.66 | 1,662,548,077.64 | 1,649,490,355.81 |
| 负债和股东权益合计 | 3,632,062,761.01 | 3,675,221,886.51 | 3,641,528,326.98 | 3,738,301,973.19 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 775,824,306.15 | 290,200,871.52 | 1,666,297,553.92 | 1,206,283,176.51 |
| 经营活动现金流出小计 | 835,841,292.32 | 487,853,509.1 | 1,619,139,546.7 | 1,295,272,217.69 |
| 经营活动产生的现金流量净额 | -60,016,986.17 | -197,652,637.58 | 47,158,007.22 | -88,989,041.18 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 100,046,114.73 | 100,039,259.73 | 169,033,235.85 | 148,856,333.7 |
| 投资活动现金流出小计 | 4,963,046.05 | 3,126,238.95 | 168,872,400.08 | 59,811,211.87 |
| 投资活动产生的现金流量净额 | 95,083,068.68 | 96,913,020.78 | 160,835.77 | 89,045,121.83 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,267,800,000 | 999,900,000 | 1,922,720,082.04 | 1,590,993,800.12 |
| 筹资活动现金流出小计 | 1,266,907,550.43 | 945,986,675.25 | 1,938,086,631.94 | 1,416,229,551.17 |
| 筹资活动产生的现金流量净额 | 892,449.57 | 53,913,324.75 | -15,366,549.9 | 174,764,248.95 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | - |
| 现金及现金等价物净增加额 | 35,958,532.08 | -46,826,292.05 | 31,952,293.09 | 174,820,329.6 |
| 期末现金及现金等价物余额 | 211,803,731.02 | 129,018,906.89 | 175,845,198.94 | 318,713,235.45 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 35,958,532.08 | - | 31,952,293.09 | - |